Preempt future health risks.

Airfinity provides global health intelligence and analytics that decision makers can trust, understand and act upon to save lives.

Cited over 20,000 times in 2021 as a pioneer in predictive intelligence.


Analysis & Insights

AstraZeneca’s infant RSV drug Beyfortus could generate $1.1bn sales revenue
AstraZeneca’s infant RSV drug Beyfortus could generate $1.1bn sales revenue

Airfinity analysis shows Astrazeneca's monoclonal infant RSV drug could be administered to up to 3.5 million infants under one year of age in Europe once approved which would generate a potential revenue of up to $1.1bn.

Read More →

More from Airfinity
18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workersAstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccinationSales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor MolnupiravirGlobal wastage of COVID-19 vaccines could be 1.1 billion dosesAirfinity appoints its first ever Chief Product Officer, Colin WilliansKey factors hindering global oral antiviral uptakeView All →
In the News
China Is Stuck With Its Zero-Covid Policy Because of Weak Vaccines

Barron's | Sep 13, 2022

Omicron boosters are a key milestone, but aren’t likely to woo new investors to Pfizer, Moderna

CNBC | Sep 7, 2022

How nasal-spray vaccines could change the pandemic

Nature | Sep 6, 2022

Airfinity estimates a shortage of up to 55 million monkeypox vaccine doses

Cinco Días | Aug 29, 2022

View All →

A pioneer in predictive health intelligence


What's happening in a given disease area?

Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.


Identify the true need for a vaccine or a treatment.

Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.


Maximise impact to save lives

Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.

The world's most comprehensive infectious disease solutions.

Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.


New science

Market & Production


Disease & Prevalence

Learn More →

What our users say?


“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”

Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister

hm government

“Airfinity has been instrumental in our country's COVID response.”

Head of UK Government
Vaccine Task Force


“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”

Director General,

the economist

“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”

James Fransham, Data Journalist,
The Economist